Skip to main content
AmigoFish

Ep. 392 - Biotech markets: Pause before the storm?

From BioCentury This Week · · 24 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

An M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling some quality names and follow-on activity slowed. On the latest BioCentury This Week podcast, BioCentury’s analysts preview the fourth quarter (https://www.biocentury.com/article/661118), where rising bond yields and the U.S. midterms could keep financing and deal activity quiet through year-end. The analysts also discuss why late-stage misses in Lp(a), IL-6, and Factor XI are pushing developers to rethink secondary prevention (https://www.biocentury.com/article/661069) trial design, and PhRMA’s lawsuit to block CMS’s Globe Part B model, which could determine whether future administrations can impose international reference pricing without Congress.

View full story: https://www.biocentury.com/article/661134

#BiotechMarkets #DrugPricing #CardiovascularDisease #ClinicalTrials #FDA

0:00 Introduction 1:10 Biotech Market Outlook 11:40 CV Trial Design Rethink 18:24 PhRMA vs. GLOBE

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem